PTPA and non-small cell lung carcinoma: Current targeted therapies for NSCLC are predominately inhibitors of oncogenic kinases; however, only targeting kinases ignores the critical role of phosphatases, like protein phosphatase 2A (PP2A), as regulators of protein phosphorylation in abating resistance mechanisms to RAS/MAPK inhibition (RAS/MAPKi).